NSCLC

This early-stage trial tests a new drug called TB511, alone or with pembrolizumab, in 12 adults with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that stopped responding to standard treatments. The goal is to find the safest dose and see if it can shrink tu…

This study tests whether adding the allergy medicine diphenhydramine to standard immunotherapy (toripalimab) and chemotherapy can improve outcomes for people with stage IIA-IIIB non-small cell lung cancer that can be removed by surgery. About 120 participants will receive either …

This study tests a new combination of two drugs—gemcitabine (a chemotherapy) and ivonescimab (a targeted therapy)—in 47 people with advanced non-small cell lung cancer whose disease got worse after standard immunotherapy. The goal is to see if the combo can shrink tumors and offe…

This study tests whether a new immunotherapy drug (iparomlimab and tuvonralimab) combined with targeted radiation (SBRT) can help control early-stage non-small cell lung cancer. About 28 adults with stage I-IIB disease will receive the treatment. The goal is to see if the combina…

This study tests whether giving two drugs (SHR-A1811 and adebelimumab) before surgery can shrink or eliminate tumors in people with early-stage lung cancer that has a specific genetic change (HER2 alteration). About 40 adults with resectable non-small cell lung cancer will receiv…

This study tests whether a drug called bozitinib, combined with chemotherapy, can shrink tumors in people with a specific genetic lung cancer (MET-altered) before they have surgery. About 34 adults with stage IIA to IIIC non-small cell lung cancer will receive the treatment and t…

This study tests a drug called Vebreltinib given for 8 weeks before surgery in people with a specific type of lung cancer (stage IIA-IIIB NSCLC with METex14 skipping mutation). The goal is to see if the drug can shrink or control the tumor, making surgery more effective. About 30…

This study tests a new drug called GFH276 in people with advanced cancers that have a specific gene change (RAS mutation). The cancers include pancreatic, lung, and colorectal cancer. The goal is to find a safe dose and see if the drug can shrink tumors. About 450 adults aged 18-…

This study tests whether a new combination of targeted radiation, immunotherapy, and chemotherapy can improve outcomes for people with early-stage non-small-cell lung cancer before they have surgery. The treatment is given before surgery to shrink the tumor and increase the chanc…

This study tests a new drug called rilapentib alpha combined with chemotherapy for people with stage II or III non-small cell lung cancer that can be removed with surgery. Participants receive the drug combo before surgery to shrink the tumor, then continue the new drug alone for…

This study tests whether adding a new drug, SYS6010, to the standard treatment osimertinib can help people with a certain type of advanced lung cancer (EGFR-mutant NSCLC) live longer without their cancer growing. About 680 adults aged 18-75 will be split into two groups: one gets…

This study tests a new targeted drug (limertinib) combined with radiation therapy as a first treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the brain. The goal is to see if the combination can better control br…

This study looks at how safe and effective the drug SHR-A1811 is for Chinese patients with advanced or spreading non-small cell lung cancer that has a specific change in the HER2 gene. About 1,000 adults will be followed as they receive the drug in regular medical practice. The g…

This study tests a daily pill called iruplinalkib for people with early-stage (stage IA) ALK-positive non-small cell lung cancer who have high-risk factors. After surgery to remove the tumor, participants take the pill for up to three years to see if it helps keep the cancer from…

This study tests a new drug combination given before surgery for people with early-stage non-small cell lung cancer that does not have certain gene changes. The treatment uses focused radiation, an immunotherapy drug, and a targeted therapy to shrink tumors without standard chemo…

This study tests a device that uses both cold and radiofrequency energy to treat small lung tumors during a standard bronchoscopy. About 20 people with early-stage lung cancer will receive the treatment, then have the tumor surgically removed to check the device's effect. The goa…

This study looks at whether a short program of four weekly counseling sessions before lung cancer surgery can lower anxiety and depression in patients. About 138 adults scheduled for lung cancer surgery will be split into three groups: one getting the counseling, one that refuses…

This study tests whether a personalized exercise program is practical for people with stage II or III lung cancer before they start treatment. Twenty participants will follow the program, and researchers will track how many complete at least 80% of the sessions. The goal is to se…

This study looks at 300 lung cancer patients whose tumors did not completely disappear after immunotherapy and surgery. Researchers will use advanced gene testing to find hidden genetic changes that might explain why the treatment didn't work fully. The goal is to better understa…

This study tests a non-invasive device that delivers low-intensity electric fields (TTFields) to people with early-stage lung cancer before they have surgery. The main goal is to see how these fields affect certain cancer-related genes, not to cure the disease. About 18 participa…